In this episode of Healthcare Logic for Growth, we break down what healthcare startups need to do to succeed - and why so many fail. We cover the five biggest success factors, including solving a real problem, proving outcomes, building the payment model early, fitting into clinical workflows, and scaling with trust. We also look at five common failure patterns, including weak validation, no reimbursement path, long sales cycles, poor workflow fit, and trust breakdowns.

We use real-world examples from Omada Health, Oshi Health, Zocdoc, Theranos, and Babylon Health to show what success and failure look like in practice. If you’re building, investing in, or marketing to healthcare startups, this episode is a practical guide to what actually matters. Key Topics - Why healthcare startups are different from consumer tech. - The five things a healthcare startup needs to do to succeed. - The five most common reasons healthcare startups fail. - Lessons from real companies with public-facing data. - Questions founders should ask to stay on track. - A go-forward strategy for building a durable healthcare company.

Sources Referenced in This Episode:

- AMA case study on Omada Health, highlighting evidence-based care, data-powered coaching, connected devices, and care coordination.

- Omada public platform information on outcomes and care delivery.

- AMA and related public materials on Oshi Health, including multidisciplinary GI care, outcomes, and cost savings.

- Zocdoc’s public milestone update on profitability, cash flow, provider growth, and business model improvements.

- STAT’s analysis of why healthcare startups fail, especially around reimbursement, pricing, and operational complexity.

- Public materials on Theranos’s failures and regulatory issues.

- Public reporting and analysis on Babylon Health’s collapse and reimbursement challenges.

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.

Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic

The MFN drug pricing framework - what began as voluntary agreements with sixteen of the largest pharmaceutical companies - is now moving toward mandatory rules that will reach smaller biotechs and pharma companies. At the same time, a 100% pharmaceutical tariff takes effect September 29th for smaller manufacturers, with a lower 20% rate available only to companies that have engaged the MFN framework and filed domestic manufacturing plans.

BIO International opens at the same time of this published episode, June 22nd. So, in this episode, we flip the script: instead of treating MFN as a threat, we show small life science companies how to turn it into a commercial advantage - with five specific actions you can take starting this week.

Sources Referenced in This Episode:

Skadden Arps — "MFN Drug Pricing and Impact on International Life Sciences Licensing Deals" — June 1, 2026

BioTech Briefings / Gibson Dunn — "MFN Drug Pricing in 2026: Voluntary Deals Are Giving Way to Mandatory Rules" — March 2026

Clinical Leader — "U.S. Pharma Tariffs and MFN Become Law After April 2 Update" — April 2026

AJMC — "MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage" — June 2026

BioSpace — "Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026"

PharmExec — "What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications" — April 2026

BIO International Convention 2026 — San Diego, June 22–25, 2026 — convention.bio.org

White House Council of Economic Advisers — "Savings from Most-Favored-Nation Drug Pricing Policy" — May 2026

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.

Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic

Healthcare is full of great products that never became great businesses. In this first episode of the Healthcare Startup Revenue Series, we break down 4 of the structural barriers that accelerate performance:

• Buyer vs. user separation
• Long purchasing cycles
• The evidence requirement
• Economic model misalignment

Whether you’re still in your first year of commercial activity or stuck at early customers and unable to scale, this episode gives you a foundation to consider.

Sources Referenced:

• Rock Health Digital Health Funding Report - https://rockhealth.com/
• HIMSS Healthcare Procurement Stakeholder Research - https://www.himss.org/
• Health Care Transformation Task Force - Value-Based Care Contracting Frameworks - https://hcttf.org/

About Life Science Logic:

Life Science Logic helps hospitals, HHAs, healthcare associations, small life science and healthcare companies go to market smarter, not more expensively. We combine commercial strategy, competitive intelligence, and planning with a disciplined, cost-conscious approach - delivering the rigor of a top-tier consultancy without the expanded overhead. The result? Our clients cut unnecessary spending, improve commercial efficiency, and give better performance earlier.

Ready to spend less and perform better? Learn more at https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.

Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic

On May 1, 2026, the CMS BALANCE Model went live - opening the door for Medicaid agencies to begin enrolling in a new federal framework that expands GLP-1 coverage for obesity and metabolic disease. The Medicare GLP-1 Bridge follows on July 1st, giving Medicare Part D beneficiaries access to these drugs at $50 per month. Most of the conversation has focused on Novo Nordisk and Eli Lilly. This episode is for everyone else. We break down what BALANCE actually does, what the commercial ecosystem around it looks like for small pharma, biotech, digital health companies, home health agencies, and hospitals - and five specific actions you should be taking right now.

Sources Referenced in This Episode:

• KFF - 'What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge' - Updated May 11, 2026
• CMS Innovation Center - BALANCE Model Official Page and Implementation Timeline - cms.gov
• CMS - 'Innovation Insight: Affordability of GLP-1s Takes Next Step with BALANCE Model RFAs' - March 9, 2026
• Eli Lilly - Updated Statement on CMMI BALANCE Model and Medicare GLP-1 Bridge - March 2026
• Fierce Healthcare - 'CMS Launching Payment Model to Boost Access to GLP-1s in Medicaid, Part D' - December 2025
• IQVIA - 'Outlook for Obesity in 2026: From Consolidation to Acceleration' - January 2026
• MMM Online - '2026 Is the Year GLP-1s Grow Up' - February 2026
• AJMC - 'MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage' - May 22, 2026

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at Eric@lifesciencelogic.com.

Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic

Healthcare is deploying AI tools at more than twice the rate of the broader economy — and for the first time at meaningful scale, the ROI is real and documented. In this episode, we unpack the NVIDIA State of AI in Healthcare 2026 survey and this week's Healthcare IT News report on AI payment alignment to answer the question every small healthcare company is quietly asking: what does the AI inflection point actually mean for my business right now? We cover three real-world scenarios across six audience segments — hospitals, home health agencies, digital health startups, pharma, biotech, and healthcare associations — and close with six specific actions you can take this week.

Links:

• NVIDIA -'State of AI in Healthcare and Life Sciences: 2026 Trends' -February 2026
• Healthcare IT News - 'Realizing the full value of AI in healthcare will require better alignment between payment models, regulatory expectations and outcomes' -May 21, 2026
• Healthcare Dive - 'Top Healthcare AI Trends in 2026' -January 2026
• BCG/BCG X -'How AI Agents and Tech Will Transform Health Care in 2026' - March 2026
• Wolters Kluwer -'2026 Healthcare AI Trends: Insights from Experts' -December 2025
• Chief Healthcare Executive -'AI in Health Care: 26 Leaders Offer Predictions for 2026' - January 2026
• Bipartisan Policy Center - 'FDA Oversight: Understanding the Regulation of Health AI Tools' - March 2026
• Precedence Research - AI in Healthcare Market Size Forecast - November 2025

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at Eric@lifesciencelogic.com.

Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic

On May 1st, 2026, Nebraska became the first state in the country to enforce Medicaid work requirements under the One Big Beautiful Bill Act - the sweeping federal law that includes nearly a trillion dollars in Medicaid cuts over ten years. Montana goes live July 1st. Iowa in December. And 43 states are federally required to follow by January 1st, 2027. In this episode, we break down what this means for small life science and healthcare companies, why the 2027 framing is the wrong planning frame, and five specific steps you should be taking right now to protect your revenue model and your commercial strategy.

Sources Referenced in This Episode:

• NPR - 'It's Day 1 of Medicaid Work Requirements in Nebraska,' May 1, 2026
• KFF - 'An Early Look at Policy Decisions as States Get Ready to Implement Work Requirements,' May 2026
• GoodRx Health - 'New Medicaid Work Requirements (2026): What to Know,' May 2026
• AJMC - 'Medicaid Work Requirements Set to Leave Millions Without Insurance,' May 2026
• Becker's Hospital Review - 'Hospitals Brace for New Wave of Federal Cuts,' April 2026
• Center on Budget and Policy Priorities (CBPP) - 'States Need More Time to Prepare,' April 2026
• KFF - 'How Might Federal Medicaid Cuts Affect Rural Areas?' September 2025
• Fierce Healthcare - '2026 Outlook: The Domino Effect of Medicaid Cuts,' March 2026

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at Eric@lifesciencelogic.com.

Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic

On April 23, 2026, the FDA and CMS announced the RAPID coverage pathway - a new program designed to cut the historically long gap between FDA device authorization and Medicare coverage from a year or more down to as little as two months. For early-stage life science device companies, this changes the commercial math.

In this episode, we break down exactly what RAPID is, who qualifies, what it means for your launch strategy, and five specific steps you should be taking right now.

1. Determine your eligibility right now. If you have or are pursuing Breakthrough Device designation for a Class II or Class III device with a significant Medicare-age patient population, RAPID may apply to you.
2. Audit your IDE study design immediately. The RAPID pathway requires that your clinical outcomes be agreed upon by both FDA and CMS in advance. If your current study design was built solely around FDA's evidentiary requirements, you may have a gap.
3. Request a CMS engagement meeting. CMS has committed to early and frequent engagement with RAPID-eligible device companies during development. That is not a formality - it is a strategic resource built into the pathway.
4. Update your commercial launch model. If you have been modeling a one-to-two year gap between FDA authorization and Medicare coverage, and RAPID applies to your device, your timeline assumptions are out of date.
5. Engage the public comment process. When the RAPID proposed procedural notice hits the Federal Register, you will have 60 days to submit comments.

Sources Referenced in This Episode:

• CMS.gov - RAPID Coverage Pathway Press Release, April 23, 2026
• FDA.gov - Joint CMS/FDA Announcement, April 23, 2026
• Foley Hoag LLP - RAPID Pathway Legal Analysis, April 2026
• Healthcare Dive - 'CMS, FDA unveil speedier Medicare coverage pathway,' April 23, 2026
• STAT News - 'CMS, FDA propose new, faster coverage for breakthrough devices,' April 23, 2026
• Arnold & Porter - Regulatory & Reimbursement Analysis, April 2026

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at lifesciencelogic.com or reach me at Eric@lifesciencelogic.com.

CONNECT

• Website: https://lifesciencelogic.com/
• Email: Eric@lifesciencelogic.com

Biotech in 2026 is operating inside a Triple Threat. In this episode, we break down the three forces hitting simultaneously: capital pressure that now demands commercial readiness alongside clinical proof, clinical complexity that has turned trial design into a commercial decision, and commercial infrastructure gaps that show up at the worst possible moment - right when you need them most.

If you're leading an early-stage biotech, preparing for a Series B, or building out your first commercial team, this episode gives you an honest picture of the landscape and three clear actions you can take right now.

WHY THIS MATTERS

The playbook that worked three years ago no longer applies. Capital is concentrating at later stages and investors are asking commercial questions earlier. Payers are demanding evidence that gets built into trial design - not bolted on after approval. And the gap between FDA approval and commercial success has not gotten any shorter.

What's different in 2026 is that these three pressures are compounding each other. A weak commercial story makes fundraising harder. A misaligned trial design creates payer problems at launch. And a company that hasn't built commercial infrastructure in parallel with clinical development finds itself scrambling when the window opens. This episode is about seeing all three threats clearly - and acting on them now.

WHAT WE COVER

• The 2026 biotech landscape - what's changed and what hasn't
• Threat 1: Capital Pressure - why investors now require commercial readiness alongside clinical proof
• Threat 2: Clinical Complexity - why trial design is now a commercial decision, not just a regulatory one
• Threat 3: Commercial Readiness - the infrastructure problem that shows up at the worst possible time
• The Myth/Misconception: 'We'll figure out commercial after approval' - and why that window is now closed
• How the three threats compound each other - and what that means for your planning horizon

YOUR GO FORWARD STRATEGY — 3 ACTIONS FROM THIS EPISODE

1 - Map your trial endpoints against payer coverage criteria - do this before your next protocol amendment, not after approval

2 - Build your one-page commercial narrative before your next investor meeting - your clinical story needs a commercial chapter

3 - Book one payer conversation this quarter - not to pitch, but to listen and learn what they'll actually need to see

CONNECT

• Website: https://lifesciencelogic.com/
• Email: Eric@lifesciencelogic.com

Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic